Wong KO et al. Antinuclear Antibody, Rheumatoid Factor, and Cyclic-Citrullinated Peptide Tests for Evaluating Musculoskeletal Complaints in Children. Rockville (MD): Agency for Healthcare Research and Quality (US); March 2012.
Stratton K, Ford A, Rusch E, Wright E, eds. Adverse Effects of Vaccines, Evidence and Causality. Washington (DC): National Academies Press (US); 2011 Aug 25.
Malottki K et al. Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a Tumour Necrosis Factor Inhibitor: A Systematic Review and Economic Evaluation. Southampton (UK): NIHR Evaluation, Trials and Studies Coordinating Centre (UK); March 2011.
Dretzke J et al. A Systematic Review and Economic Evaluation of the Use of Tumour Necrosis Factor-Alpha (TNF-a) Inhibitors, Adalimumab and Infliximab, for Crohn’s Disease. Southampton (UK): NIHR Evaluation, Trials and Studies Coordinating Centre (UK); February 2011.
Rodgers M et al. Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation. Southampton (UK): NIHR Evaluation, Trials and Studies Coordinating Centre (UK); February 2011.
Wang D et al. Palivizumab for Immunoprophylaxis of Respiratory Syncytial Virus (RSV) Bronchiolitis in High-Risk Infants and Young Children: Systematic Review and Additional Economic Modelling of Subgroup Analyses. Southampton (UK): NIHR Evaluation, Trials and Studies Coordinating Centre (UK); January 2011.
Frank SA. Immunology and Evolution of Infectious Disease. Princeton (NJ): Princeton University Press; 2002.
Janeway CA, Travers P, Walport M, Shlomchik MJ. Immunobiology, 5th edition, The Immune System in Health and Disease. New York: Garland Science; 2001.